Precision BioSciences Inc
NASDAQ:DTIL
Intrinsic Value
Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. [ Read More ]
The intrinsic value of one DTIL stock under the Base Case scenario is 9.92 USD. Compared to the current market price of 10.57 USD, Precision BioSciences Inc is Overvalued by 6%.
Valuation Backtest
Precision BioSciences Inc
Run backtest to discover the historical profit from buying and selling DTIL stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Precision BioSciences Inc
Current Assets | 136.4m |
Cash & Short-Term Investments | 116.7m |
Receivables | 12.8m |
Other Current Assets | 6.9m |
Non-Current Assets | 23.4m |
Long-Term Investments | 3.2m |
PP&E | 14.6m |
Intangibles | 400k |
Other Non-Current Assets | 5.2m |
Current Liabilities | 50m |
Accounts Payable | 3m |
Accrued Liabilities | 7.7m |
Short-Term Debt | 22.4m |
Other Current Liabilities | 16.9m |
Non-Current Liabilities | 90.9m |
Other Non-Current Liabilities | 90.9m |
Earnings Waterfall
Precision BioSciences Inc
Revenue
|
48.7m
USD
|
Operating Expenses
|
-92.5m
USD
|
Operating Income
|
-43.7m
USD
|
Other Expenses
|
-17.6m
USD
|
Net Income
|
-61.3m
USD
|
Free Cash Flow Analysis
Precision BioSciences Inc
DTIL Profitability Score
Profitability Due Diligence
Precision BioSciences Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
Score
Precision BioSciences Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
DTIL Solvency Score
Solvency Due Diligence
Precision BioSciences Inc's solvency score is 39/100. The higher the solvency score, the more solvent the company is.
Score
Precision BioSciences Inc's solvency score is 39/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
DTIL Price Targets Summary
Precision BioSciences Inc
According to Wall Street analysts, the average 1-year price target for DTIL is 33.66 USD with a low forecast of 19.19 USD and a high forecast of 63 USD.
Ownership
DTIL Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
DTIL Price
Precision BioSciences Inc
Average Annual Return | -31.64% |
Standard Deviation of Annual Returns | 38.54% |
Max Drawdown | -99% |
Market Capitalization | 73.1m USD |
Shares Outstanding | 6 916 240 |
Percentage of Shares Shorted | 5.14% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. The company is headquartered in Durham, North Carolina and currently employs 198 full-time employees. The company went IPO on 2019-03-28. The company is developing ex vivo allogeneic CAR T immunotherapies and in vivo therapies for genetic and infectious diseases with the application of its owned ARCUS genome editing platform. The firm's ARCUS platform is designed to deliver therapeutic-grade genome editing. Its ARCUS genome editing technology is for deoxyribonucleic acid (DNA) genome insertion, deletion and repair. Its ARCUS is based on a naturally occurring genome editing enzyme, I-CreI, that evolved in the algae Chlamydomonas reinhardtii to make specific cuts and DNA insertions in cellular DNA. Its Ex vivo Allogeneic CAR T Immunotherapy pipeline offers programs, including PBCAR0191, PBCAR19B, PBCAR269A and CD19 Combination with Foralumab. Its in-vivo Gene Correction pipeline offers three preclinical programs, including PBGENE-PCSK9, PBGENE-PH1 and PBGENE-HBV. Its subsidiaries include Precision PlantSciences, Inc. and Precision BioSciences UK Limited.
Contact
IPO
Employees
Officers
The intrinsic value of one DTIL stock under the Base Case scenario is 9.92 USD.
Compared to the current market price of 10.57 USD, Precision BioSciences Inc is Overvalued by 6%.